Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference
Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), will present at Digestive Disease Week (DDW) 2022 in San Diego, California, from May 21-24. Professor Yehuda Ringel, Biomica's CSO, is scheduled to speak on May 22 from 4:00 PM to 5:30 PM PDT about the anti-inflammatory effects of a live bacterial consortium for treating Inflammatory Bowel Disorders (IBD). This presentation will share findings from pre-clinical research on microbiome-based drug development. Biomica focuses on microbiome therapeutics for gastrointestinal disorders and bacterial resistance.
- None.
- None.
REHOVOT, Israel, May 16, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the Digestive Disease Week (DDW 2022) Conference taking place May 21-24, 2022, in San Diego, California.
DDW is the world's premier meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
Professor Yehuda Ringel, CSO of Biomica, will be presenting on May 22, 2022 from 4:00 PM to 5:30 PM PDT. The presentation is entitled, "Anti-Inflammatory effect of a rationally designed live bacterial consortium based on microbiome functional genomic analysis for treatment of Inflammatory Bowel Disorders (IBD)". Professor Ringel will present data from the discovery and pre-clinical animal research of Biomica's IBD microbiome-based drug development project.
Professor Ringel will be available for one-on-one meetings at the conferences, and those interested should be in touch with Professor Ringel and/or with the investor or public relations team.
About Biomica:
Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN). For more information, please visit www.biomicamed.com.
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Contact:
Kenny Green
US Investor Relations
E: IR@evogene.com
T: +1 212 378 8040
View original content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-2022-digestive-disease-week-ddw-conference-301547694.html
SOURCE Biomica Ltd.
FAQ
When is Biomica presenting at the DDW 2022 conference?
What is the topic of Biomica's presentation at DDW 2022?
Where is the Digestive Disease Week 2022 conference held?
Who is the CSO of Biomica presenting at DDW 2022?
What focus areas does Biomica specialize in?
